“Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s10. https://doi.org/10.25251/skin.1.supp.9.